By Brendan Pierson (Reuters) – Arkansas’s attorney general on Wednesday accused drugmakers and pharmacy benefit managers of colluding to drive up the price of insulin drugs, the latest in a series of lawsuits to take aim at skyrocketing insulin costs. The lawsuit, filed in Pulaski County, Arkansas state court, targets Eli Lilly and Co, Novo Nordisk A/S and Sanofi SA, which together make the vast majority of the insulin drugs sold in the United States. It also names the nation’s leading pharmacy benefit managers (PBMs) – UnitedHealth Group Inc subsidiary Optum Inc, CVS Health Corp’s CVS Caremar…